NASAL ADMINISTRATION OF BENZODIAZEPINES
Particulate formulations of benzodiazepines, such as diazepam, are used for nasal administration of diazepine drugs to patients. Multimodal particulate formulations of benzodiazepines and methods for their use, e.g. by nasal administration for the treatment of seizure, are also provided.
1 . A composition for nasal administration of a medicament comprising a first population of particles having a first effective average particle size and a second population of particles having a second effective average particle size, wherein the first effective average particle size is at least 1.5 times that of the second effective average particle size.
2 . The composition of claim 1 , wherein the medicament comprises at least one benzodiazepine.
3 . The composition of claim 2 , wherein the medicament comprises at least one benzodiazepine selected from the group consisting of: alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
4 . The pharmaceutical composition of claim 1 , wherein the first population of particles has a average size in the range of about 25 to about 7000 nm and the second population of particles has a average size in the range of about 500 to about 10,000 nm.
5 . The pharmaceutical composition of claim 1 , wherein the difference between the average particle size of the first and second populations is greater than about 100 nm, greater than about 200 nm, greater than about 500 nm, greater than about 1000 nm, greater than about 2000 nm, greater than about 3000 nm, greater than about 4000 nm, greater than about 5000 nm, greater than about 6000 nm, greater than about 7000 nm, greater than about 8000 nm, greater than about 9000 nm or greater than about 10,000 nm.
6 . The pharmaceutical composition of claim 1 , wherein the difference between the average particle size of the first and second particle populations is greater than about 10%, greater than about 20% or greater than about 30% of the average particle size of the second population of particles.
7 . A method of using a composition of claim 1 , comprising administering an effective amount of the composition to the nose by administering a therapeutically effective amount of the composition to at least one nostril.
8 . A pharmaceutical particulate composition for nasal delivery of a medicament comprising particulates having a multimodal particle size distribution.
9 . The pharmaceutical particulate composition of claim 8 , wherein the particulates have a bimodal particle size distribution.
10 . The pharmaceutical composition of claim 9 , wherein the medicament comprises at least one benzodiazepine.
11 . The pharmaceutical composition of claim 10 , wherein the medicament comprises at least one benzodiazepine selected from the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
12 . The pharmaceutical composition of claim 8 , wherein the particles have an effective average size greater than about 500 nm, 1000 nm, greater than about 2000 nm, greater than about 4000 nm or greater than 5000 nm.
13 . A method of using a composition of claim 8 , comprising administering an effective amount of the composition to the nose by administering a therapeutically effective amount of the composition to at least one nostril.
14 . An aerosol composition of an aqueous suspension or dispersion of nanoparticulate benzodiazepine particles, wherein: the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) less than or equal to about 1000 μm and the nanoparticulate benzodiazepine particles have an effective average particle size of less than about 5000 nm.
15 . The aerosol composition of claim 14 , wherein the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
16 . The aerosol composition of claim 15 , wherein the aerosol composition can be administered in a drug dosage in less than about 60 seconds.
17 . A method of using an aerosol composition of claim 14 , comprising administering an effective amount of the composition to the nose by spraying a therapeutically effective amount of the composition into at least one nostril.
18 . A method of administering a benzodiazepine drug to a patient, comprising administering to the nose or nasal cavity an effective amount of an aerosol composition of an aqueous suspension or dispersion of nanoparticulate benzodiazepine particles, wherein: the droplets of the aerosol have a mass median aerodynamic diameter (MMAD)less than or equal to about 1000 μm and the nanoparticulate benzodiazepine particles have an effective average particle size of less than about 5000 nm.
19 . The method of claim 18 , wherein the nanoparticulate benzodiazepine particles comprise at least on member of the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
20 . A pharmaceutical composition for nasal administration of benzodiazepine comprising benzodiazepine particles and one or more surface active agents adsorbed to a surface thereof.
21 . The pharmaceutical composition of claim 20 , wherein the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
22 . A method of using an aerosol composition of claim 20 , comprising administering an effective amount of the composition to the nose by administering a therapeutically effective amount of the composition to at least one nostril.
23 . A method of administering a benzodiazepine drug to a patient, comprising administering to the patient's nose or nasal cavity a pharmaceutical composition comprising particles of a benzodiazepine drug having a surface active agent adsorbed to a surface thereof.
24 . The composition of claim 8 , wherein the composition is a non-aqueous dispersion or suspension of nanoparticulate benzodiazepine particles.
25 . The non-aqueous dispersion or suspension of nanoparticulate benzodiazepine particles of claim 24 , wherein the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
26 . A method of using a non-aqueous dispersion or suspension of nanoparticulate benzodiazepine of claim 24 , comprising administering an effective amount of the dispersion or suspension to the nose by administering a therapeutically effective amount of the composition to at least one nostril.
27 . A method of administering a benzodiazepine drug to a patient, comprising administering to the patient's nose or nasal cavity a pharmaceutical composition comprising a non-aqueous dispersion or suspension of nanoparticulate benzodiazepine particles according to claim 24 .
28 . The composition of claim 8 , wherein the composition is an aqueous dispersion or suspension of nanoparticulate benzodiazepine particles.
29 . The composition of claim 28 , wherein the nanoparticulate benzodiazepine particles comprise at least one member of the group consisting of alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, medazepam, lorazepam, mexazolam, prazepam, quazepam, triazolam, temazepam, loprazolam, and pharmaceutically acceptable salts and combinations thereof.
30 . A method of using a non-aqueous dispersion or suspension of nanoparticulate benzodiazepine of claim 29 , comprising administering an effective amount of the dispersion or suspension to the nose by administering a therapeutically effective amount of the composition to at least one nostril.
31 . A method of administering a benzodiazepine drug to a patient, comprising administering to the patient's nose or nasal cavity a pharmaceutical composition comprising an aqueous dispersion or suspension of nanoparticulate benzodiazepine particles according to claim 28 .